Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022

Dr Subbiah discusses research from the 2022 ASCO Annual Meeting, including phase 2 data (NCT04165772) in mismatch repair–deficient, locally advanced rectal cancer; findings from DESTINY-Breast04 (NCT03734029) in HER2-low unresectable and/or metastatic breast cancer; a first-in-human study (NCT04585750) in TP53-mutant advanced solid tumors; and data from LIBRETTO-001 (NCT03157128) in RET fusion–positive solid tumors.

Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

August 1st 2022

Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.

Ongoing Studies With Novel Agents in HER2+ Metastatic Breast Cancer

August 1st 2022

Before sharing a final review of treatment options for HER2+ metastatic breast cancer, expert oncologists highlight ongoing clinical trials in this setting.

Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

August 1st 2022

A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.

HER2+ mBC: Practical Selection and Sequencing of Therapy

August 1st 2022

Comprehensive discussion on how oncologists may practically select and sequence novel treatment approaches in HER2+ metastatic breast cancer.

Understanding the Role of pCR in Early-Stage TNBC Opens Doors for Tailored Treatment

July 30th 2022

As ongoing research efforts are shifting further into personalized care, Hope S. Rugo, MD, FASCO discusses how pathologic complete response and the predictive value of residual cancer burden scoring are becoming a pivotal end point for the changing triple-negative breast cancer landscape.

How Low Can We Go? Metastatic Breast Cancer Enters a New Era of HER2 Classification

July 30th 2022

Erika P. Hamilton, MD, shares how multidisciplinary collaboration between pathologist and breast oncologists is key to staying abreast of not only the classification-actionable HER2 mutations in metastatic breast cancer but also the evolving definition of expression.

Chemotherapy Benefit May Stem From Ovarian Function Suppression in Premenopausal HR+/HER2- Breast Cancer

July 30th 2022

Nicholas P. McAndrew, MD, MSCE, discusses considerations to take when examining the relationship between chemotherapy, ovarian function suppression, and treatment benefits experienced by patients with hormone receptor–positive, HER2-negative breast cancer.

HER2-Directed Treatment Escalation or De-escalation Necessitates Careful Consideration in HER2+ Breast Cancer

July 29th 2022

Sara A. Hurvitz, MD, explains when de-escalation therapy can play a role in patients with HER2-positive breast cancer.

Oral SERDs Could Fulfill Unmet Need in ESR1-Mutant, ER-Positive Breast Cancer

July 29th 2022

Aditya Bardia, MD, MPH, discusses recent and ongoing trials evaluating oral SERDs in estrogen receptor–positive breast cancer, the effect of ESR1 mutations on treatment efficacy, and how the use of ctDNA continues to evolve across the breast cancer space.

Sylvester Experts Explain the Most Promising Advances in Cancer Research and Treatment Presented at ASCO 2022

July 28th 2022

Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.

Next-Generation Sequencing Platforms for Late-Stage HR+ Breast Cancer

July 27th 2022

Shared insight on next-generation sequencing platforms, plasma- and tumor-based, for patients with late-stage HR+ breast cancer.

Optimizing Breast Cancer Management: Molecular Targets and Platforms for Testing

July 27th 2022

Expert oncologists identify molecular targets in breast cancer and review available testing platforms in the current treatment paradigm.

HR+/HER2- Breast Cancer: Excitement for Upcoming Clinical Trial Readouts

July 27th 2022

Key opinion leaders in breast cancer management share their excitement for data that will be released at the annual ASCO meeting in 2022 or the near future.

Addressing Unmet Needs in HR+/HER2- Metastatic Breast Cancer

July 27th 2022

Before closing out their discussion on CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, experts highlight remaining unmet needs in this setting.

Dr. Jatoi on SLN Biopsy in ER-Positive, HER2-Negative Breast Cancer

July 25th 2022

Ismail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.

FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer

July 25th 2022

The FDA has accepted and granted priority review to a supplemental biologics license application for the use of trastuzumab deruxtecan in the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received 1 prior therapy in the metastatic setting.

HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?

July 25th 2022

Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.

Novel ADCs Under Investigation in Triple-Negative Breast Cancer

July 25th 2022

Expert oncologists review novel ADCs in TNBC and consider how their approval may impact sequencing of therapy in this setting.

Novel Treatment Approaches to Brain Metastases in HER2+ Breast Cancer

July 25th 2022

Focusing on the management of brain metastases in HER2+ metastatic breast cancer, panelists share trial data on tucatinib and trastuzumab deruxtecan.